<DOC>
	<DOCNO>NCT02131948</DOCNO>
	<brief_summary>It well known hormone insulin lower blood glucose part act directly liver reduce hepatic glucose production . Animal study show hormone insulin act brain indirectly low glucose production liver . We aim test whether true human give insulin intranasally . It previously show nasal spray deliver insulin directly brain without affect circulate insulin concentration .</brief_summary>
	<brief_title>Regulation Endogenous Glucose Production Brain Insulin Action</brief_title>
	<detailed_description>Each study participant admit hospital evening prior study . Following admission study participant provide standardized dinner . At 7am ( t=0 ) next day begin prim , constant intravenous infusion d2 glucose ( stable isotope glucose , enrichment measure gas chromatography mass spectrometry , allow u calculate endogenous glucose production rate ) continue 8 hour . At time ( 7am ) pancreatic clamp start describe 8 hour . Blood sample analyse glucometer instant blood glucose reading At 9 ( +120 minute ) intranasal placebo insulin administer . The insulin ( Humalog Lispro 100 IU/ml , Eli Lily , Canada ) placebo ( diluent ) transfer meter nasal device ( Pharmasystems , Ontario UPC : 063636 802721 , Item 10271 ) immediately prior use . This device dispense 0.1ml ( 10 IU ) per puff . 4X0.1 ml puffs/vials ( 2 per nostril ) administer rate 2 ( one nostril ) every 60 second . Blood drawn t=0 , 30 , 60 , 120 every 10 minute thereafter 6 hour . In order match peripheral lispro concentration study visit , small dose Humalog ( lispro ) insulin administer intravenously 9am , placebo arm study . Based pharmacokinetics Humalog lispro ( personal communication Eli Lilly ) , propose administer 0.005 IU/kg 30 minute . 20 % dextrose administer maintain euglycemia necessary . Insulin , glucagon , glucose isotopic enrichment measure . The enrichment data glucose infusion use calculate steady state glucose production .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Men woman , age 18 60 year 2 . Body mass index 2027 . 3 . Hemoglobin normal range . 4 . Normal glucose tolerance response 75g , 2hr oral glucose tolerance test 5 . Women reproductive age contraception ( oral contraceptive pill intrauterine device/coil ) least 2 month prior study . Volunteers take part study previously approve protocol eligible participate amend study , provide inform consent Study participant history hepatitis/hepatic disease active within previous two year . 2 . Any current previous history biliary disease ( include gall stone , biliary atresia cholecystitis ) pancreatitis . 3 . Any current previous history endocrine disease , dyslipidemia malignancy 4 . Any significant active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , renal ( Cr &gt; 1.5 mg/dL ) genitourinary , hematological system , severe uncontrolled treated untreated hyper/ hypotension ( sit diastolic BP &gt; 100 systolic &gt; 180 systolic BP &lt; 100 ) proliferative retinopathy 5 . Use immunosuppressive agent time study 6 . Allergy study medication 7 . Pregnancy breastfeed 8 . Heavy smoker 9 . Prior nasoduodenal tube insertion fluoroscopic guidance . 10 . Fasting blood glucose &gt; 6.0 mmol/l know diabetes . 11 . Any history MI clinically significant , active , cardiovascular history include history arrhythmia 's conduction delay ECG , unstable angina , decompensated heart failure . 12 . Any nasal pathology likely affect absorption insulin insertion nasoduodenal tube . 13 . Any laboratory value : AST &gt; 2x ULN ; ALT &gt; 2x ULN TSH &gt; 6 mU/l 14 . Current addiction alcohol substance abuse determine investigator . 15 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 16 . Taking regular prescription nonprescription medication time study . Occasional use medication acetoaminophen Tylenol 1 use natural health product may permit discretion investigator . 17 . Will donate blood three month prior three month post study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Insulin resistance</keyword>
	<keyword>Brain insulin action</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>